A promising study published in The New England Journal of Medicine showed that semaglutide, the compound in Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease. The findings of this major clinical trial could transform how doctors treat people with chronic kidney disease, a disease which affects millions of adults in the United States alone.
